Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments

The BNT162b2 vaccine is globally used for preventing morbidity and mortality related to COVID-19. Cancer patients have had priority for receiving the vaccine due to their diminished immunity. This study reports the response rate of administering the third and fourth vaccine doses to cancer patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Agbarya, Abed, Sarel, Ina, Ziv-Baran, Tomer, Schwartz, Orna, Shechtman, Yelena, Kozlener, Ella, Khoury, Rasha, Sheikh-Ahmad, Mohammad, Saiegh, Leonard, Swaid, Forat, Ahmad, Asala Abu, Janzic, Urska, Brenner, Ronen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594524/
https://www.ncbi.nlm.nih.gov/pubmed/37873772
http://dx.doi.org/10.3390/diseases11040128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594524/
https://www.ncbi.nlm.nih.gov/pubmed/37873772
http://dx.doi.org/10.3390/diseases11040128

Ejemplares similares